Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis

A. Ravelli, B. Ramenghi, G. Di Fuccia, N. Ruperto, L. Zonta, A. Martini

Research output: Contribution to journalArticlepeer-review


We retrospectively investigated, in 19 children with systemic-onset juvenile chronic arthritis (SoJCA), the possible influence on the outcome of methotrexate (MTX) therapy of several independent variables, including age at onset of juvenile chronic arthritis, disease duration and severity of the disease at baseline. The dosage of MTX ranged from 7.5 to 11.0 mg/m2/week (median 9.3 mg/m2/week) and was given as a single, oral weekly dose. After 6 months of treatment, 12 (63%) patients were judged as responders on grounds of a ≥ 50% reduction in the number of joints with active arthritis and/or an articular severity score; 7 (37%) did not respond to therapy. When the baseline values of the selected variables were compared, we found that the responder group had, with respect to the non-responder group, a lower percentage of radiographic lesions (p

Original languageEnglish
Pages (from-to)428-432
Number of pages5
JournalActa Paediatrica, International Journal of Paediatrics
Issue number4
Publication statusPublished - 1994


  • Disease duration
  • Juvenile chronic arthritis
  • Methotrexate
  • Radiographic lesions
  • Treatment outcome

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis'. Together they form a unique fingerprint.

Cite this